<?xml version="1.0" encoding="UTF-8"?><marc:collection xmlns:marc="http://www.loc.gov/MARC21/slim">
  <marc:record>
    <marc:leader>00000nam  2200000za 4500</marc:leader>
    <marc:controlfield tag="001">9.843655</marc:controlfield>
    <marc:controlfield tag="003">CaOODSP</marc:controlfield>
    <marc:controlfield tag="005">20241007153052</marc:controlfield>
    <marc:controlfield tag="007">cr |||||||||||</marc:controlfield>
    <marc:controlfield tag="008">171003s2017    onc     ob   f000 0 eng d</marc:controlfield>
    <marc:datafield tag="020" ind1=" " ind2=" ">
      <marc:subfield code="a">978-0-660-09692-6</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="040" ind1=" " ind2=" ">
      <marc:subfield code="a">CaOODSP</marc:subfield>
      <marc:subfield code="b">eng</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="043" ind1=" " ind2=" ">
      <marc:subfield code="a">n-cn---</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="086" ind1="1" ind2=" ">
      <marc:subfield code="a">MR4-61/2017E-PDF</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="245" ind1="0" ind2="0">
      <marc:subfield code="a">CIHR assessment of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain </marc:subfield>
      <marc:subfield code="h">[electronic resource].</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="260" ind1=" " ind2=" ">
      <marc:subfield code="a">Ottawa : </marc:subfield>
      <marc:subfield code="b">Canadian Institutes of Health Research, </marc:subfield>
      <marc:subfield code="c">c2017.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="300" ind1=" " ind2=" ">
      <marc:subfield code="a">17 p.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="500" ind1=" " ind2=" ">
      <marc:subfield code="a">Issued also in French under title: Évaluation des IRSC des Recommandations canadiennes sur l’utilisation des opioïdes pour le traitement de la douleur chronique non cancéreuse.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="500" ind1=" " ind2=" ">
      <marc:subfield code="a">Cover title.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="504" ind1=" " ind2=" ">
      <marc:subfield code="a">Includes bibliographical references.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="520" ind1=" " ind2=" ">
      <marc:subfield code="a">“In 2010, recognizing the need to improve safe opioid prescribing practices, a national group of physicians and researchers developed the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. This guideline provided recommendations to medical professionals on prescribing opioids safely and effectively. Once the 2010 guideline was published, McMaster University’s Michael G. DeGroote National Pain Centre assumed responsibility for keeping it current by highlighting new evidence. In the years following, the Government of Canada provided funding, through the Canadian Institutes of Health Research and Health Canada, to McMaster University researchers to update the 2010 guideline with new evidence. The revised 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain (the 2017 Canadian Guideline) was published in the Canadian Medical Association Journal (CMAJ) on May 8, 2017. Following its release, The Globe and Mail reported that McMaster University did not exclude medical experts who had received income from opioid manufacturers from the 2017 Canadian Guideline’s voting panel. In response to public criticism, the Minister of Health directed CIHR to assess what impact, if any, the potential conflict of interest had on the scientific rigour of the 2017 Canadian Guideline. This review aimed to determine whether the 2017 Canadian Guideline provides unbiased, evidence-based guidance to clinicians on opioid prescribing practices”--p. 3.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="530" ind1=" " ind2=" ">
      <marc:subfield code="a">Issued also in bilingual print format.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="692" ind1="0" ind2="7">
      <marc:subfield code="2">gccst</marc:subfield>
      <marc:subfield code="a">Prescription drugs</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="692" ind1="0" ind2="7">
      <marc:subfield code="2">gccst</marc:subfield>
      <marc:subfield code="a">Safety standards</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="692" ind1="0" ind2="7">
      <marc:subfield code="2">gccst</marc:subfield>
      <marc:subfield code="a">Review</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="710" ind1="2" ind2=" ">
      <marc:subfield code="a">Canadian Institutes of Health Research.</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="775" ind1="0" ind2="8">
      <marc:subfield code="t">Évaluation des IRSC des Recommandations canadiennes sur l’utilisation des opioïdes pour le traitement de la douleur chronique non cancéreuse </marc:subfield>
      <marc:subfield code="w">(CaOODSP)9.843656</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="776" ind1="0" ind2="#">
      <marc:subfield code="t">CIHR assessment of the Canadian guideline for opioids for chronic non-cancer pain </marc:subfield>
      <marc:subfield code="w">(CaOODSP)9.843661</marc:subfield>
    </marc:datafield>
    <marc:datafield tag="856" ind1="4" ind2="0">
      <marc:subfield code="q">PDF</marc:subfield>
      <marc:subfield code="s">800 KB</marc:subfield>
      <marc:subfield code="u">https://publications.gc.ca/collections/collection_2017/irsc-cihr/MR4-61-2017-eng.pdf</marc:subfield>
    </marc:datafield>
  </marc:record>
</marc:collection>
